This release has been disseminated on behalf of Oncotelic Therapeutics, which may include a paid advertisement.   NetworkNewsWire Editorial Coverage: The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce toxicity and improve patient outcomes. Traditional oral or IV drugs often face poor bioavailability and limited tumor targeting — a major bottleneck in cancer treatment success. Recent breakthroughs in nanomedicine are making headlines, as the FDA and global regulatory bodies increasingly endorse nanocarrier-based delivery for complex drugs. This surge underscores a larger industry trend: the race to improve how drugs reach and act within the body. Oncotelic Therapeutics Inc.’s (OTCQB: OTLC) (profile) Deciparticle(TM) platform exemplifies this shift. It offers a novel approach to increase the bioavailability and therapeutic index of existing cancer drugs, potentially transforming underperforming compounds into next-generation therapies. The recent advancement of Sapu-003 into human trials signals real-world momentum behind this vision, showing how innovation in delivery science can unlock new value across multiple drug candidates. Oncotelic Therapeutics is focused on making its mark in the oncology treatment space, along with other innovative leaders such as IO Biotech Inc. (NASDAQ: IOBT), Novartis AG (NYSE: NVS), Bicara Therapeutics Inc. (NASDAQ: BCAX) and Pfizer Inc. (NYSE: PFE) The pharmaceutical industry is entering an inflection point driven by the recognition that highly potent cancer drugs are only as effective as their ability to reach tumors with sufficient concentration. Oncotelic Therapeutics’ Deciparticle technology directly addresses this effective drug-delivery need with a modular, ultra-high-efficiency nanomedicine delivery engine. Sapu-003 has now advanced into first-in-human clinical trials in Australia, marking a pivotal moment for the platform’s external validation. The projected $500-billion-plus nanomedicine market by 2032 is anchored more by delivery innovation than by new molecular discoveries. Deciparticle-enabled therapies could deliver materially more effective treatment with lower toxicity. The Global Shift Toward Smarter Drug Delivery The pharmaceutical industry is entering an inflection point driven by the recognition that highly potent cancer drugs are only as effective as their ability to reach tumors with sufficient concentration. Many promising oncology drugs fail not because the therapy lacks biological power, but because the body absorbs only a fraction of the intended dose. Conventional oral and IV therapies struggle with poor solubility, steep metabolism and imprecise biodistribution, forcing high doses and resulting in systemic toxicity. This is especially problematic in mTOR inhibitors, kinase inhibitors, and vascular-disrupting agents, where dose-limiting toxicity can halt development even when preclinical data were strong. As a result, the industry is increasingly prioritizing drug-delivery innovation as much as drug discovery itself. Nanomedicine, the engineering of sub-200-nanometer drug carriers, is rapidly becoming the leading solution to address absorption inefficiencies and off-target toxicity. These platforms are designed not only to protect the drug from premature degradation but also control its release and guide it more precisely to tumor environments. Leading market research estimates that the global nanomedicine market could surpass $500 billion by 2032, driven by oncology-focused breakthroughs that materially improve drug absorption and targeting. Within oncology, nanocarrier delivery has accelerated following regulatory validations such as FDA approvals of nanoparticle-formulated chemotherapies and RNA therapies. These new formulations are not simply incremental improvements; they can transform once-marginal drugs into category-changing assets. As precision medicine evolves from mutation-targeting

This release has been disseminated on behalf of Oncotelic Therapeutics, which may include a paid advertisement.   NetworkNewsWire Editorial Coverage: The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce toxicity and improve patient outcomes. Traditional oral or IV drugs often face poor bioavailability and limited tumor targeting — a major bottleneck in cancer treatment success. Recent breakthroughs in nanomedicine are making headlines, as the FDA and global regulatory bodies increasingly endorse nanocarrier-based delivery for complex drugs. This surge underscores a larger industry trend: the race to improve how drugs reach and act within the body. Oncotelic Therapeutics Inc.’s (OTCQB: OTLC) (profile) Deciparticle(TM) platform exemplifies this shift. It offers a novel approach to increase the bioavailability and therapeutic index of existing cancer drugs, potentially transforming underperforming compounds into next-generation therapies. The recent advancement of Sapu-003 into human trials signals real-world momentum behind this vision, showing how innovation in delivery science can unlock new value across multiple drug candidates. Oncotelic Therapeutics is focused on making its mark in the oncology treatment space, along with other innovative leaders such as IO Biotech Inc. (NASDAQ: IOBT), Novartis AG (NYSE: NVS), Bicara Therapeutics Inc. (NASDAQ: BCAX) and Pfizer Inc. (NYSE: PFE) The pharmaceutical industry is entering an inflection point driven by the recognition that highly potent cancer drugs are only as effective as their ability to reach tumors with sufficient concentration. Oncotelic Therapeutics’ Deciparticle technology directly addresses this effective drug-delivery need with a modular, ultra-high-efficiency nanomedicine delivery engine. Sapu-003 has now advanced into first-in-human clinical trials in Australia, marking a pivotal moment for the platform’s external validation. The projected $500-billion-plus nanomedicine market by 2032 is anchored more by delivery innovation than by new molecular discoveries. Deciparticle-enabled therapies could deliver materially more effective treatment with lower toxicity. The Global Shift Toward Smarter Drug Delivery The pharmaceutical industry is entering an inflection point driven by the recognition that highly potent cancer drugs are only as effective as their ability to reach tumors with sufficient concentration. Many promising oncology drugs fail not because the therapy lacks biological power, but because the body absorbs only a fraction of the intended dose. Conventional oral and IV therapies struggle with poor solubility, steep metabolism and imprecise biodistribution, forcing high doses and resulting in systemic toxicity. This is especially problematic in mTOR inhibitors, kinase inhibitors, and vascular-disrupting agents, where dose-limiting toxicity can halt development even when preclinical data were strong. As a result, the industry is increasingly prioritizing drug-delivery innovation as much as drug discovery itself. Nanomedicine, the engineering of sub-200-nanometer drug carriers, is rapidly becoming the leading solution to address absorption inefficiencies and off-target toxicity. These platforms are designed not only to protect the drug from premature degradation but also control its release and guide it more precisely to tumor environments. Leading market research estimates that the global nanomedicine market could surpass $500 billion by 2032, driven by oncology-focused breakthroughs that materially improve drug absorption and targeting. Within oncology, nanocarrier delivery has accelerated following regulatory validations such as FDA approvals of nanoparticle-formulated chemotherapies and RNA therapies. These new formulations are not simply incremental improvements; they can transform once-marginal drugs into category-changing assets. As precision medicine evolves from mutation-targeting t

NetworkNewsWire Editorial Coverage: Artificial intelligence (“AI”) is making inroads into every corner of medical technology, perhaps none more urgently than imaging. In breast cancer detection, where early diagnosis can mean the difference between life and death, AI-enhanced modalities present a chance to leap beyond the limits of mammography, tomosynthesis, and MRI. Globally, breast cancer remains one of the most common cancers in women. According to the World Health Organization (“WHO”), more than 2.3 million women were diagnosed with breast cancer in 2022, and approximately 670,000 women died from the disease globally. In the United States, the American Cancer Society (“ACS”) projects that 316,950 new invasive breast cancer cases will be diagnosed among women this year. The urgent, life-saving need for earlier and more accurate detection creates a powerful opportunity for innovation in diagnostic imaging. Amid this global challenge, companies advancing breast cancer diagnostics are entering a high-impact field. Among them, Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (profile) stands out with its next-generation IzoView Breast CT Imaging System, a dedicated 3D imaging platform designed to improve detection accuracy, particularly for women with dense breast tissue. IzoView joins an elite group of companies, including Hologic Inc. (NASDAQ: HOLX), GE HealthCare Technologies Inc. (NASDAQ: GEHC), Nano-X Imaging Ltd. (NASDAQ: NNOX) and Oracle Corp. (NYSE: ORCL), that are focused on playing a transformative role in the use of AI in the medical imaging sector. Izotropic Corporation has advanced its plan to commercialize IzoView, a dedicated breast CT scanner purpose-built to address dense breast imaging, a high-priority and underserved segment. One of Izotropic’s key selling points is that IzoView is engineered for economic scalability and extensibility. Izotropic’s strategy relies on a proprietary AI image reconstruction algorithm, trained over 15 years of specialized breast CT data and held as a trade secret. Izotropic’s vision for IzoView extends beyond imaging hardware; it is structured to become a node within the larger AI-enabled diagnostic ecosystem. According to analysts, the global breast imaging market is projected to grow at ~8.6% CAGR between 2023 and 2030, reaching approximately $9 billion by 2030. AI and 3D Imaging: The New Frontiers of Detection The convergence of AI and three-dimensional (“3D”) medical imaging marks a turning point in diagnostic medicine. While traditional mammography has been a life-saving screening tool for decades, it is inherently constrained by its two-dimensional projection format and the physical compression required to visualize internal structures. In dense breast tissue, present in more than one-half of women, lesions can be obscured or distorted, leading to reduced sensitivity and delayed detection. Research confirms that dense fibroglandular tissue can mask or mimic breast cancers, thereby lowering diagnostic accuracy and increasing the risk of missed cases, with one study reporting that mammography performance declines significantly in dense breasts, as overlapping tissue often conceals malignancies. The emergence of AI-driven image reconstruction and analysis now offers a transformative solution to these long-standing challenges. Advanced algorithms can enhance contrast, reduce image noise and identify subtle patterns invisible to human interpretation. AI-based methods have also been shown to improve CT image quality while maintaining or reducing radiation dose, producing clearer and safer diagnostic results. In breast imaging specifically, recent reviews highlight that deep learning systems can augment or even match radiologist performance in lesion detection, segmentation and classification, particularly in dense tissue or early-stage disease. This integration of AI with volumetric imaging technologies, such as tomosynthesis, MRI and dedicated breast CT, signals a

NetworkNewsWire Editorial Coverage: Artificial intelligence (“AI”) is making inroads into every corner of medical technology, perhaps none more urgently than imaging. In breast cancer detection, where early diagnosis can mean the difference between life and death, AI-enhanced modalities present a chance to leap beyond the limits of mammography, tomosynthesis, and MRI. Globally, breast cancer remains one of the most common cancers in women. According to the World Health Organization (“WHO”), more than 2.3 million women were diagnosed with breast cancer in 2022, and approximately 670,000 women died from the disease globally. In the United States, the American Cancer Society (“ACS”) projects that 316,950 new invasive breast cancer cases will be diagnosed among women this year. The urgent, life-saving need for earlier and more accurate detection creates a powerful opportunity for innovation in diagnostic imaging. Amid this global challenge, companies advancing breast cancer diagnostics are entering a high-impact field. Among them, Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (profile) stands out with its next-generation IzoView Breast CT Imaging System, a dedicated 3D imaging platform designed to improve detection accuracy, particularly for women with dense breast tissue. IzoView joins an elite group of companies, including Hologic Inc. (NASDAQ: HOLX), GE HealthCare Technologies Inc. (NASDAQ: GEHC), Nano-X Imaging Ltd. (NASDAQ: NNOX) and Oracle Corp. (NYSE: ORCL), that are focused on playing a transformative role in the use of AI in the medical imaging sector. Izotropic Corporation has advanced its plan to commercialize IzoView, a dedicated breast CT scanner purpose-built to address dense breast imaging, a high-priority and underserved segment. One of Izotropic’s key selling points is that IzoView is engineered for economic scalability and extensibility. Izotropic’s strategy relies on a proprietary AI image reconstruction algorithm, trained over 15 years of specialized breast CT data and held as a trade secret. Izotropic’s vision for IzoView extends beyond imaging hardware; it is structured to become a node within the larger AI-enabled diagnostic ecosystem. According to analysts, the global breast imaging market is projected to grow at ~8.6% CAGR between 2023 and 2030, reaching approximately $9 billion by 2030. AI and 3D Imaging: The New Frontiers of Detection The convergence of AI and three-dimensional (“3D”) medical imaging marks a turning point in diagnostic medicine. While traditional mammography has been a life-saving screening tool for decades, it is inherently constrained by its two-dimensional projection format and the physical compression required to visualize internal structures. In dense breast tissue, present in more than one-half of women, lesions can be obscured or distorted, leading to reduced sensitivity and delayed detection. Research confirms that dense fibroglandular tissue can mask or mimic breast cancers, thereby lowering diagnostic accuracy and increasing the risk of missed cases, with one study reporting that mammography performance declines significantly in dense breasts, as overlapping tissue often conceals malignancies. The emergence of AI-driven image reconstruction and analysis now offers a transformative solution to these long-standing challenges. Advanced algorithms can enhance contrast, reduce image noise and identify subtle patterns invisible to human interpretation. AI-based methods have also been shown to improve CT image quality while maintaining or reducing radiation dose, producing clearer and safer diagnostic results. In breast imaging specifically, recent reviews highlight that deep learning systems can augment or even match radiologist performance in lesion detection, segmentation and classification, particularly in dense tissue or early-stage disease. This integration of AI with volumetric imaging technologies, such as tomosynthesis, MRI and dedicated breast CT, signals a

AUSTIN, Texas, October 22, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features the return of Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments. Dr. Trieu kicked off the conversation with a major update on Oncotelic’s latest clinical milestone: the advancement of Sapu-003, a novel IV formulation of everolimus (Afinitor®) built on Oncotelic’s proprietary Deciparticle™ platform. “We’re very excited about the Sapu-003 approval to start a Phase 1 clinical trial,” he said. “This is a drug that targets breast cancer specifically… Breast cancer is roughly $30–40 billion in terms of addressable market size and [is forecast to] grow beyond that to roughly $50 billion by 2030. We feel that this drug candidate really has a lot of potential to change how breast cancer patients get treated and improve on Afinitor®, which is already a blockbuster drug.” He then explained how the company’s Deciparticle™ nanomedicine platform addresses one of the biggest limitations of current mTOR inhibitors—poor bioavailability. “If administered orally, only 10% of Afinitor® gets into the tissues, into the tumor. Bioavailability is low, so patients have to really take a lot of the drug to get enough in to kill the tumor, exposing themselves to gastric toxicity. With Sapu-003, we inject the drug directly, so 100% of the drug goes straight to the tumor… It kills off the tumor, and [there’s] a very minimal amount in the gut. You don’t have that gut toxicity that comes with oral administration.” Looking ahead, Dr. Trieu outlined an aggressive development timeline for Sapu-003 and the broader Deciparticle™ pipeline. “Our focus has always been to accelerate development as quickly as we can to get to market approval… This is an example where we took it from concept to clinical trial in less than one year… We anticipate finishing Phase 1 fairly quickly and then moving to Phase 3. So, within 2–3 years, we would like to have this drug product approved, which is faster than traditional drug development, where you’re looking at 10–15 years for approval.” Join IBN’s Carmel Fisher for a follow-up conversation with Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, as he shares how Sapu-003 and the Deciparticle™ platform are reshaping the company’s approach to oncology innovation and clinical execution. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 19 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine About Oncotelic Therapeutics Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued

AUSTIN, Texas, October 22, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features the return of Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments. Dr. Trieu kicked off the conversation with a major update on Oncotelic’s latest clinical milestone: the advancement of Sapu-003, a novel IV formulation of everolimus (Afinitor®) built on Oncotelic’s proprietary Deciparticle™ platform. “We’re very excited about the Sapu-003 approval to start a Phase 1 clinical trial,” he said. “This is a drug that targets breast cancer specifically… Breast cancer is roughly $30–40 billion in terms of addressable market size and [is forecast to] grow beyond that to roughly $50 billion by 2030. We feel that this drug candidate really has a lot of potential to change how breast cancer patients get treated and improve on Afinitor®, which is already a blockbuster drug.” He then explained how the company’s Deciparticle™ nanomedicine platform addresses one of the biggest limitations of current mTOR inhibitors—poor bioavailability. “If administered orally, only 10% of Afinitor® gets into the tissues, into the tumor. Bioavailability is low, so patients have to really take a lot of the drug to get enough in to kill the tumor, exposing themselves to gastric toxicity. With Sapu-003, we inject the drug directly, so 100% of the drug goes straight to the tumor… It kills off the tumor, and [there’s] a very minimal amount in the gut. You don’t have that gut toxicity that comes with oral administration.” Looking ahead, Dr. Trieu outlined an aggressive development timeline for Sapu-003 and the broader Deciparticle™ pipeline. “Our focus has always been to accelerate development as quickly as we can to get to market approval… This is an example where we took it from concept to clinical trial in less than one year… We anticipate finishing Phase 1 fairly quickly and then moving to Phase 3. So, within 2–3 years, we would like to have this drug product approved, which is faster than traditional drug development, where you’re looking at 10–15 years for approval.” Join IBN’s Carmel Fisher for a follow-up conversation with Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, as he shares how Sapu-003 and the Deciparticle™ platform are reshaping the company’s approach to oncology innovation and clinical execution. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 19 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine About Oncotelic Therapeutics Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued

AUSTIN, Texas, September 22, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments. To begin the interview, Dr. Trieu provided an overview of the company’s mission and therapeutic scope. “Oncotelic is a clinical-stage biotechnology company. We’re developing drugs to treat cancer and other rare diseases such as Parkinson’s and sexual dysfunction,” he said. “The team has been around for about 25 years. We originally developed Abraxane and, later, Cynviloq, and now we’re working on a lot of exciting drugs around oncology.” He then discussed how Oncotelic’s development approach sets the company apart in the biotech space. “What we have at Oncotelic is a really deep knowledge of the tumor microenvironment, as well as the regulatory pathway that we develop for each one of the drugs. When we take on an asset, we can easily build IP around it and protect it. Then, we push it out through a regulatory pathway that has the shortest timeline and highest chance of approval. That really differentiates us from everyone else.” Looking ahead, Dr. Trieu outlined the key inflection points investors should watch. “Our investors should be really looking forward to a lot of announcements from us in the next 12 months or so, both from the clinical side… as well as regulatory milestones such as IND approval, expansion into other indications, and partnership announcements… The team has been really focusing on operational execution—getting these drugs moving through clinical development, into trials, and toward approval.” Join IBN’s Carmel Fisher for a conversation with Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, to learn more about the company’s differentiated clinical pipeline and forward-looking development strategy. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 19 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine About Oncotelic Therapeutics Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics. For more information, visit the company’s website at www.Oncotelic.com About IBN IBN consists of financial brands in

AUSTIN, Texas, September 22, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments. To begin the interview, Dr. Trieu provided an overview of the company’s mission and therapeutic scope. “Oncotelic is a clinical-stage biotechnology company. We’re developing drugs to treat cancer and other rare diseases such as Parkinson’s and sexual dysfunction,” he said. “The team has been around for about 25 years. We originally developed Abraxane and, later, Cynviloq, and now we’re working on a lot of exciting drugs around oncology.” He then discussed how Oncotelic’s development approach sets the company apart in the biotech space. “What we have at Oncotelic is a really deep knowledge of the tumor microenvironment, as well as the regulatory pathway that we develop for each one of the drugs. When we take on an asset, we can easily build IP around it and protect it. Then, we push it out through a regulatory pathway that has the shortest timeline and highest chance of approval. That really differentiates us from everyone else.” Looking ahead, Dr. Trieu outlined the key inflection points investors should watch. “Our investors should be really looking forward to a lot of announcements from us in the next 12 months or so, both from the clinical side… as well as regulatory milestones such as IND approval, expansion into other indications, and partnership announcements… The team has been really focusing on operational execution—getting these drugs moving through clinical development, into trials, and toward approval.” Join IBN’s Carmel Fisher for a conversation with Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, to learn more about the company’s differentiated clinical pipeline and forward-looking development strategy. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 19 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine About Oncotelic Therapeutics Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics. For more information, visit the company’s website at www.Oncotelic.com About IBN IBN consists of financial brands in

AUSTIN, Texas, September 19, 2025 – via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth,” featuring Oncotelic Therapeutics Inc. (OTCQB: OTLC). To hear the NetworkNewsAudio version, visit LINK To read the original editorial, visit LINK At the helm of Oncotelic is Dr. Vuong Trieu, a biotech leader with a career defined by innovation and successful translation of science into practice. He has filed more than 500 patent applications and holds 75 issued patents — credentials that few industry executives can match. These patents cover a wide array of drug-development strategies, spanning oncology, immunotherapy and nanomedicine, reflecting his deep engagement in pioneering technologies. Among Trieu’s most significant achievements has been his role in developing Abraxane(R), a nanotechnology-based formulation of paclitaxel bound to albumin nanoparticles. This innovation transformed the treatment landscape for breast, lung and pancreatic cancers and became a multibillion-dollar global therapy. Similarly, he advanced Cynviloq(TM), a novel micellar formulation of paclitaxel that improved delivery while reducing toxicities, further demonstrating his ability to reinvent cancer therapy. About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics. For further information, please visit the company’s website at www.Oncotelic.com.  NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC About NetworkNewsAudio NetworkNewsAudio, a service of NetworkNewsWire (NNW), a multifaceted financial news and publishing company powered by IBN (“InvestorBrandNetwork”), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire. For more information, visit: www.NetworkNewsAudio.com NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today's markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge. Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://NNW.fm/Disclaimer Forward-Looking Statements This release contains forward-looking statements within the meaning of Sect

AUSTIN, Texas, September 19, 2025 – via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth,” featuring Oncotelic Therapeutics Inc. (OTCQB: OTLC). To hear the NetworkNewsAudio version, visit LINK To read the original editorial, visit LINK At the helm of Oncotelic is Dr. Vuong Trieu, a biotech leader with a career defined by innovation and successful translation of science into practice. He has filed more than 500 patent applications and holds 75 issued patents — credentials that few industry executives can match. These patents cover a wide array of drug-development strategies, spanning oncology, immunotherapy and nanomedicine, reflecting his deep engagement in pioneering technologies. Among Trieu’s most significant achievements has been his role in developing Abraxane(R), a nanotechnology-based formulation of paclitaxel bound to albumin nanoparticles. This innovation transformed the treatment landscape for breast, lung and pancreatic cancers and became a multibillion-dollar global therapy. Similarly, he advanced Cynviloq(TM), a novel micellar formulation of paclitaxel that improved delivery while reducing toxicities, further demonstrating his ability to reinvent cancer therapy. About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics. For further information, please visit the company’s website at www.Oncotelic.com.  NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC About NetworkNewsAudio NetworkNewsAudio, a service of NetworkNewsWire (NNW), a multifaceted financial news and publishing company powered by IBN (“InvestorBrandNetwork”), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire. For more information, visit: www.NetworkNewsAudio.com NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today's markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge. Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://NNW.fm/Disclaimer Forward-Looking Statements This release contains forward-looking statements within the meaning of Sect

AUSTIN, Texas, September 10, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Panna Sharma, President, CEO, and Director of Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform. Mr. Sharma explains the mechanisms of the drug and also provides insights into the three ongoing clinical trials for each of the potential drug-candidates that could be worth several billion USD each. During the interview, Sharma explained Lantern Pharma’s core mission and AI-driven approach.  “We like to think of ourselves as an AI-first company focused on creating cancer medicines. The problem that we’re trying to solve is a massive problem globally: about $250 billion a year is spent on research and development into new cancer medicines, yet it takes 10-to-12 years to go from an idea to an approved drug, and 93% of them fail… To me, this is a perfect problem area for top cancer minds to try to use AI, big data and computational biology to solve. That’s what our team does.” “We’re maniacally focused on driving AI first. We’ve created computational models from the ground up to focus on different types of cancers and the mechanisms behind them… Imagine being able to aggregate world-class cancer research 24 hours a day and have machine learning models compete to answer complex questions. That’s exactly what we’re doing — using AI to tackle the challenge of creating cancer medicines, with three drug candidates now dosing patients in Japan, Taiwan, and the United States.” Looking ahead, Sharma highlighted Lantern’s market positioning and outlook. “The next five to seven years, I see this as an era where many of the most difficult cancers, specifically brain cancers, we’re going to start solving for them. We recently announced a new board member who came from a brain cancer company that just got acquired, and their drug was recently approved… That was one of three brain cancer drugs approved in the last 12-to-14 months (after 17 years without any approvals) signaling a new era in precision neuro-oncology.” Join IBN’s Stuart Smith and Panna Sharma, President, CEO, and Director of Lantern Pharma, to learn more about the company’s AI-powered precision oncology platform, pipeline milestones, and vision for transforming cancer treatment. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine About Lantern Pharma Lantern Pharma is an AI company transforming the cost, time, and failure rate of oncology drug discovery and development. Lantern's proprietary AI platform RADR® uses machine learning and multiomic data to solve complex, billion-dollar drug development challenges. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has built a pipeline of promising, clinical stage drug candidates, including molecules that target novel cancer mechanisms and targets. For more information, visit the company’s website at www.LanternPharma.com About IBN IBN consists of

AUSTIN, Texas, September 10, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Panna Sharma, President, CEO, and Director of Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform. Mr. Sharma explains the mechanisms of the drug and also provides insights into the three ongoing clinical trials for each of the potential drug-candidates that could be worth several billion USD each. During the interview, Sharma explained Lantern Pharma’s core mission and AI-driven approach.  “We like to think of ourselves as an AI-first company focused on creating cancer medicines. The problem that we’re trying to solve is a massive problem globally: about $250 billion a year is spent on research and development into new cancer medicines, yet it takes 10-to-12 years to go from an idea to an approved drug, and 93% of them fail… To me, this is a perfect problem area for top cancer minds to try to use AI, big data and computational biology to solve. That’s what our team does.” “We’re maniacally focused on driving AI first. We’ve created computational models from the ground up to focus on different types of cancers and the mechanisms behind them… Imagine being able to aggregate world-class cancer research 24 hours a day and have machine learning models compete to answer complex questions. That’s exactly what we’re doing — using AI to tackle the challenge of creating cancer medicines, with three drug candidates now dosing patients in Japan, Taiwan, and the United States.” Looking ahead, Sharma highlighted Lantern’s market positioning and outlook. “The next five to seven years, I see this as an era where many of the most difficult cancers, specifically brain cancers, we’re going to start solving for them. We recently announced a new board member who came from a brain cancer company that just got acquired, and their drug was recently approved… That was one of three brain cancer drugs approved in the last 12-to-14 months (after 17 years without any approvals) signaling a new era in precision neuro-oncology.” Join IBN’s Stuart Smith and Panna Sharma, President, CEO, and Director of Lantern Pharma, to learn more about the company’s AI-powered precision oncology platform, pipeline milestones, and vision for transforming cancer treatment. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine About Lantern Pharma Lantern Pharma is an AI company transforming the cost, time, and failure rate of oncology drug discovery and development. Lantern's proprietary AI platform RADR® uses machine learning and multiomic data to solve complex, billion-dollar drug development challenges. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has built a pipeline of promising, clinical stage drug candidates, including molecules that target novel cancer mechanisms and targets. For more information, visit the company’s website at www.LanternPharma.com About IBN IBN consists of

AUSTIN, Texas, September 4, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Robert Thast, CEO of Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers. To begin the interview, Thast discussed Izotropic’s mission: commercializing its FDA-aligned IzoView Breast CT Imaging System to close critical gaps in early cancer detection. “Screening is the first line of defense; it’s where lives are saved or not. Current standard of care misses a lot of cancers and is not particularly good at finding aggressive cancers in the early stages. With our Breast CT technology, we can see cancers as small as 2 millimeters. Current standard of care is 11 millimeters average. That’s a big difference—between 12 and 18 months earlier—which could mean the difference between finding it and treating it or having it get past the point of no return.” Thast also spoke to Izotropic’s intellectual property strategy, competitive outlook, and long-term positioning in the imaging space. “We have recently announced an AI development and capability that no one else has and may never have. We expect this technology will become increasingly accepted over time, and the majors will have to get involved if they intend to maintain their market share… In terms of protecting our position, we have a portfolio of patents, trade secrets, and products… The majors are certainly going to have the muscle to get in the game — there’s no question about that. I think it’d be a lot less expensive for them to buy something like IzoView, and I expect that’s what will happen as we move forward. We believe we will be a takeover target.” He then outlined Izotropic’s commercialization strategy, including a phased rollout in Europe and the U.S., supported by clinical validation and significant early demand. “From a revenue standpoint, our launch will be focused primarily on selling to hospitals, medical facilities, and imaging clinics. Those will be focused on the EU first, followed by the United States… Between the U.S. and Europe, you’re looking at almost 50% of the world market for one of these devices… The FDA study is a clear mandate. If we secure FDA approval, really the world is wide open to us.” Join IBN’s Carmel Fisher and Robert Thast, CEO of Izotropic Corp., to learn more about the company’s AI-powered precision oncology platform, pipeline milestones, and vision for transforming cancer treatment. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine About Izotropic More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca. About IBN IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs

AUSTIN, Texas, September 4, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Robert Thast, CEO of Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers. To begin the interview, Thast discussed Izotropic’s mission: commercializing its FDA-aligned IzoView Breast CT Imaging System to close critical gaps in early cancer detection. “Screening is the first line of defense; it’s where lives are saved or not. Current standard of care misses a lot of cancers and is not particularly good at finding aggressive cancers in the early stages. With our Breast CT technology, we can see cancers as small as 2 millimeters. Current standard of care is 11 millimeters average. That’s a big difference—between 12 and 18 months earlier—which could mean the difference between finding it and treating it or having it get past the point of no return.” Thast also spoke to Izotropic’s intellectual property strategy, competitive outlook, and long-term positioning in the imaging space. “We have recently announced an AI development and capability that no one else has and may never have. We expect this technology will become increasingly accepted over time, and the majors will have to get involved if they intend to maintain their market share… In terms of protecting our position, we have a portfolio of patents, trade secrets, and products… The majors are certainly going to have the muscle to get in the game — there’s no question about that. I think it’d be a lot less expensive for them to buy something like IzoView, and I expect that’s what will happen as we move forward. We believe we will be a takeover target.” He then outlined Izotropic’s commercialization strategy, including a phased rollout in Europe and the U.S., supported by clinical validation and significant early demand. “From a revenue standpoint, our launch will be focused primarily on selling to hospitals, medical facilities, and imaging clinics. Those will be focused on the EU first, followed by the United States… Between the U.S. and Europe, you’re looking at almost 50% of the world market for one of these devices… The FDA study is a clear mandate. If we secure FDA approval, really the world is wide open to us.” Join IBN’s Carmel Fisher and Robert Thast, CEO of Izotropic Corp., to learn more about the company’s AI-powered precision oncology platform, pipeline milestones, and vision for transforming cancer treatment. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine About Izotropic More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca. About IBN IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs

AUSTIN, Texas, August 27, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. To begin the interview, Climaco explained the devastating nature of glioblastoma and CNS Pharmaceuticals’ commitment to changing the outlook for patients facing this aggressive brain cancer. “The problem for patients and clinicians in the space is that the cancers take place in the brain behind the blood-brain barrier, which is this very specialized network of cells that prevents otherwise helpful drugs from reaching the site of the cancer.… We believe that is the reason why a cancer like glioblastoma remains one of the two greatest unmet needs in oncology today, the other being pancreatic cancer… There is no cure. Patients have very little hope. Our mission is to change that completely, and we think we have the drugs to do it.” Reflecting on the company’s response to the berubicin trial, he described how CNS Pharmaceuticals maintained its momentum and repurposed its clinical infrastructure to accelerate the development of a second promising candidate. “When you have a drug development company, you’ve got to realize that 90% of oncology drug trials fail. Those are the odds that you’re facing… That doesn’t dissuade us at all, because we know these drugs work. We have to prove that; that is our job. So, when we pivoted from our berubicin study to our TPI 287 program, we didn’t miss a beat. We have repurposed all of the work that we did to develop a global clinical network for berubicin over to our TPI program. We really just seamlessly moved forward on that.” Looking ahead, Climaco outlined the company’s broader ambitions and made the case for its potential in underserved cancer markets. “When you look at the opportunities in the space that a drug like berubicin or TPI 287 could have, not just in the primary brain cancer space, but in the metastatic space, in triple-negative breast cancer – where 40% of patients have a metastasis to the brain – the multiple and the size of the potential market for these drugs is absolutely enormous… We have demonstrated what I believe is absolutely world-class operational expertise and the ability to bring a trial through to completion on time and on budget. We’ll do it again with TPI, and we hope that we’ll have a positive result and be on our way to a drug approval. Join IBN’s Stuart Smith and John Climaco, CEO of CNS Pharmaceuticals, to learn more about the company’s vision, clinical programs, and unwavering focus on advancing treatment for brain cancer patients. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. Th

AUSTIN, Texas, August 27, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. To begin the interview, Climaco explained the devastating nature of glioblastoma and CNS Pharmaceuticals’ commitment to changing the outlook for patients facing this aggressive brain cancer. “The problem for patients and clinicians in the space is that the cancers take place in the brain behind the blood-brain barrier, which is this very specialized network of cells that prevents otherwise helpful drugs from reaching the site of the cancer.… We believe that is the reason why a cancer like glioblastoma remains one of the two greatest unmet needs in oncology today, the other being pancreatic cancer… There is no cure. Patients have very little hope. Our mission is to change that completely, and we think we have the drugs to do it.” Reflecting on the company’s response to the berubicin trial, he described how CNS Pharmaceuticals maintained its momentum and repurposed its clinical infrastructure to accelerate the development of a second promising candidate. “When you have a drug development company, you’ve got to realize that 90% of oncology drug trials fail. Those are the odds that you’re facing… That doesn’t dissuade us at all, because we know these drugs work. We have to prove that; that is our job. So, when we pivoted from our berubicin study to our TPI 287 program, we didn’t miss a beat. We have repurposed all of the work that we did to develop a global clinical network for berubicin over to our TPI program. We really just seamlessly moved forward on that.” Looking ahead, Climaco outlined the company’s broader ambitions and made the case for its potential in underserved cancer markets. “When you look at the opportunities in the space that a drug like berubicin or TPI 287 could have, not just in the primary brain cancer space, but in the metastatic space, in triple-negative breast cancer – where 40% of patients have a metastasis to the brain – the multiple and the size of the potential market for these drugs is absolutely enormous… We have demonstrated what I believe is absolutely world-class operational expertise and the ability to bring a trial through to completion on time and on budget. We’ll do it again with TPI, and we hope that we’ll have a positive result and be on our way to a drug approval. Join IBN’s Stuart Smith and John Climaco, CEO of CNS Pharmaceuticals, to learn more about the company’s vision, clinical programs, and unwavering focus on advancing treatment for brain cancer patients. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. Th

AUSTIN, Texas, August 8, 2025 – via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas,” featuring Soligenix Inc. (NASDAQ: SNGX). To hear the NetworkNewsAudio version, visit LINK To read the original editorial, visit LINK Soligenix Inc. is advancing HyBryte, its late-stage therapy for cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer that primarily affects older adults. HyBryte has shown strong promise as a first-line treatment option for early-stage CTCL, a market estimated at nearly $1 billion globally, with 70% of that opportunity in the U.S. The therapy has already received orphan drug designations in both the U.S. and Europe, as well as FDA Fast Track status. Unlike traditional treatments that can take a year or more to show efficacy, HyBryte demonstrated statistically significant results in just six weeks in its initial phase 3 trial. A second confirmatory phase 3 study, FLASH2, is now underway in the U.S. and Europe and is designed to provide further validation of HyBryte’s safety and effectiveness, with top-line results expected in 2026. HyBryte's safety profile stands out in a treatment space where many existing options carry significant side effects, including DNA damage and long-term carcinogenic risks. The therapy’s use of synthetic hypericin activated by non-carcinogenic visible light — rather than ultraviolet light — offers a safer alternative, especially for older patients. With minimal systemic absorption and strong responses across both patch and plaque lesions, HyBryte has the potential to redefine the standard of care for CTCL. Soligenix's advancements in this rare disease area highlight the growing urgency and opportunity in addressing complex conditions that disproportionately affect aging populations. About Soligenix Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, the company’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease. The company’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company’s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”). For further information, visit the company’s website at Soligenix Inc. About NetworkNewsAudio NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a

AUSTIN, Texas, August 8, 2025 – via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas,” featuring Soligenix Inc. (NASDAQ: SNGX). To hear the NetworkNewsAudio version, visit LINK To read the original editorial, visit LINK Soligenix Inc. is advancing HyBryte, its late-stage therapy for cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer that primarily affects older adults. HyBryte has shown strong promise as a first-line treatment option for early-stage CTCL, a market estimated at nearly $1 billion globally, with 70% of that opportunity in the U.S. The therapy has already received orphan drug designations in both the U.S. and Europe, as well as FDA Fast Track status. Unlike traditional treatments that can take a year or more to show efficacy, HyBryte demonstrated statistically significant results in just six weeks in its initial phase 3 trial. A second confirmatory phase 3 study, FLASH2, is now underway in the U.S. and Europe and is designed to provide further validation of HyBryte’s safety and effectiveness, with top-line results expected in 2026. HyBryte's safety profile stands out in a treatment space where many existing options carry significant side effects, including DNA damage and long-term carcinogenic risks. The therapy’s use of synthetic hypericin activated by non-carcinogenic visible light — rather than ultraviolet light — offers a safer alternative, especially for older patients. With minimal systemic absorption and strong responses across both patch and plaque lesions, HyBryte has the potential to redefine the standard of care for CTCL. Soligenix's advancements in this rare disease area highlight the growing urgency and opportunity in addressing complex conditions that disproportionately affect aging populations. About Soligenix Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, the company’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease. The company’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company’s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”). For further information, visit the company’s website at Soligenix Inc. About NetworkNewsAudio NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE American: CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated. And while cancer is the initial focus for Calidi, the company has also begun to assess the potential of this technology in other areas of large unmet need such as autoimmune disease. Calidi is joining an elite group of high-quality companies focused on making a difference in the world of cancer and genetic medicines, including Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), CG Oncology Inc. (NASDAQ: CGON), Roche (OTCQX: RHHBY) and Merck & Co. Inc. (NYSE: MRK). To view the full editorial, visit https://nnw.fm/NwefQ About Calidi Biotherapeutics Calidi Biotherapeutics is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease. The company’s proprietary Redtail platform represents a decade of development and expertise in designing viral vectors that can evade immune detection allowing for systemic delivery and distal sites of disease in oncology and, potentially, other indications. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations. The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications. For more information, visit the company’s website at www.CalidiBio.com NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://nnw.fm/CLDI About NetworkNewsAudio NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire. For more information, visit: www.NetworkNewsAudio.com About NetworkNewsWire NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public c

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE American: CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated. And while cancer is the initial focus for Calidi, the company has also begun to assess the potential of this technology in other areas of large unmet need such as autoimmune disease. Calidi is joining an elite group of high-quality companies focused on making a difference in the world of cancer and genetic medicines, including Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), CG Oncology Inc. (NASDAQ: CGON), Roche (OTCQX: RHHBY) and Merck & Co. Inc. (NYSE: MRK). To view the full editorial, visit https://nnw.fm/NwefQ About Calidi Biotherapeutics Calidi Biotherapeutics is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease. The company’s proprietary Redtail platform represents a decade of development and expertise in designing viral vectors that can evade immune detection allowing for systemic delivery and distal sites of disease in oncology and, potentially, other indications. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations. The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications. For more information, visit the company’s website at www.CalidiBio.com NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://nnw.fm/CLDI About NetworkNewsAudio NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire. For more information, visit: www.NetworkNewsAudio.com About NetworkNewsWire NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public c